Minireviews
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Endosc. Aug 16, 2017; 9(8): 359-367
Published online Aug 16, 2017. doi: 10.4253/wjge.v9.i8.359
Use and barriers to chromoendoscopy for dysplasia surveillance in inflammatory bowel disease
Richa Shukla, Mark Salem, Jason K Hou
Richa Shukla, Mark Salem, Jason K Hou, Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, United States
Jason K Hou, Houston VA HSR&D Center of Excellence, Michael E. DeBakey VAMC, Houston, TX 77030, United States
Author contributions: Shukla R contributed in the literature review and primary authorship of the manuscript; Salem M and Hou JK contributed in literature review and editorial input in the manuscript; all authors approved of the final draft submitted.
Conflict-of-interest statement: Hou JK has received research funding from Redhill Biosciences, Coronado Biosciences, Celgene, Pfizer Inc. Hou JK serves on the speaker bureau for Abbvie, Janssen, and UCB pharmaceuticals.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jason K Hou, MD, MS, Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, BCM901, Houston, TX 77030, United States. jkhou@bcm.edu
Telephone: +1-713-7980950 Fax: +1-713-7980951
Received: January 28, 2017
Peer-review started: February 9, 2017
First decision: March 22, 2017
Revised: April 13, 2017
Accepted: July 7, 2017
Article in press: July 10, 2017
Published online: August 16, 2017
Processing time: 195 Days and 3 Hours
Abstract

Traditionally, patients with inflammatory bowel disease (IBD) have been thought to be at increased risk of developing colitis-associated colorectal cancer. Although there are recent data suggesting that rates of colitis-associated cancer in IBD patients is declining, current guidelines still recommend regular dysplasia surveillance for early detection and prevention of neoplasia in patients with IBD. White-light endoscopy with random biopsies has been the traditional approach for dysplasia detection; however, newer technologies and approaches have emerged. One method, dye-based chromoendoscopy, has the potential to detect more dysplasia. However, longitudinal data to showing a benefit in morbidity or mortality from the use of chromoendoscopy are still lacking. Many societies have included recommendation on the use of chromoendoscopy with targeted biopsies as a method of surveillance for colitis - associated colorectal cancer. This narrative review seeks to outline data on dysplasia detection as well as barriers to the implementation of dye-based chromoendoscopy for the prevention and early detection of colitis-associated colorectal cancer.

Keywords: Chromoendoscopy; Inflammatory bowel disease; Dysplasia surveillance

Core tip: Patients with inflammatory bowel disease (IBD) are at an increased risk of developing colorectal cancer. Current guidelines recommend surveillance for early of neoplasia in patients with IBD. White-light endoscopy with random biopsies has been the traditional approach for dysplasia detection. Dye-based chromoendoscopy has the potential to detect more dysplasia. Many societies have endorsed the use of chromoendoscopy with targeted biopsies as a method of surveillance for colitis associated colorectal cancer. This review seeks to outline data on dysplasia detection as well as barriers to the implementation of chromoendoscopy for the prevention and early detection of colitis associated colorectal cancer.